Login to Your Account



Clinic Roundup


Thursday, August 11, 2011
Adolor Corp., of Exton, Pa., reported top-line data from two randomized, double-blind, placebo-controlled Phase II trials of ADL5945 for opioid-induced constipation. When dosed twice daily, high-dose ADL5945 significantly increased the weekly number of spontaneous bowel movements vs. placebo (3.4 SBMs vs. 1.4 SBMs; p = 0.0003).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription